Arm A is subdivided into three cohorts: cohort A-1 (Ziftomeniob + FLAG-IDA), cohort A-2 (Ziftomenib plus LDAC), and cohort A-3 (Ziftomenib plus Gilteritinib in NPM1/FLT3 double mutant AML). This evidence concerns the gene NPM1 and acute myeloid leukemia.